GET DAILY SIGNALSNutriband (NTRB) Retreats -27.7% in 30 Days After September Surge
Key Takeaways
- Nutriband (NTRB) closed at $5.95 on October 27, 2026, down roughly 27.7% from its $8.23 close 30 days earlier, after touching a 52-week high near $9 in late September.
- The pullback largely reflects profit-taking and cooling speculative momentum following an exceptionally sharp September advance rather than a single negative fundamental event.
- Over the trailing three months, the stock remains up about 95% from its late-July level near $3.05, underscoring the extreme volatility of this small-cap life-sciences name.
- Nutriband's lead asset is AVERSA Fentanyl, an abuse-deterrent transdermal patch being advanced toward clinical development and, ultimately, a New Drug Application (NDA) filing.
- The September 30 expiration of 910,904 public warrants (strike price $6.43) removed a near-term catalyst, and the company later reported 272,671 warrants exercised for roughly $1.75 million in gross proceeds.
- For more detail on this ticker's valuation and outlook, explore additional pages covering Price Targets, Earnings, and Forecast.
Company Overview and Market Position
Nutriband Inc. is a U.S.-based pharmaceutical company headquartered in Orlando, Florida, focused on developing transdermal (patch-based) pharmaceutical products. Its core proprietary platform, AVERSA, incorporates aversive agents into transdermal patches to deter the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The company's lead product candidate, AVERSA Fentanyl, combines a generic fentanyl patch with the AVERSA technology and is being positioned as a potential first abuse-deterrent fentanyl patch. Nutriband has also outlined pipeline applications for AVERSA buprenorphine and AVERSA methylphenidate, and it holds a commercial development and clinical supply agreement with Kindeva Drug Delivery. Because AVERSA Fentanyl follows the FDA's 505(b)(2) pathway and may require only a single Human Abuse Liability (Phase 1) study, investors follow the stock closely for regulatory and clinical milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
In the trailing 30 days, NTRB declined from $8.23 on September 28 to $5.95 on October 27, a drop of approximately 27.7%. The stock reached its 52-week high during the prior week, closing at $8.99 on September 24 and printing an intraday high around $9.19 on September 25, meaning shares have since retreated roughly 34% from that peak.
The longer-term picture is materially different. From a late-July level near $3.05, NTRB more than doubled at its peak and still trades roughly 95% higher as of late October, even after the recent pullback. This contrast illustrates a stock that has experienced both a powerful multi-month rally and a sharp near-term correction. From what I see, the volatility here is typical for a name of this size.
What Drove the Recent 30-Day Move
The 30-day decline is best understood as a reversal of the momentum that drove the stock higher in September. NTRB entered the period near its 52-week high after rallying from a September 3 open around $4.72 to an $8.99 close on September 24, a move of roughly 90%. That advance was amplified by speculation around the company's AVERSA platform and by an approaching warrant-expiration deadline.
Once the September 30 warrant expiration passed, a key short-term catalyst was removed, and shares began to give back gains as momentum cooled and investors locked in profits. The company subsequently disclosed on October 13 that 272,671 public warrants were exercised at $6.43 per share for approximately $1.75 million in gross proceeds. Separately, Nutriband filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to strengthen intellectual-property protection around its transdermal abuse-deterrent technology. Despite these positive corporate updates, the stock's elevated volatility and thin trading liquidity contributed to continued downside pressure.
Quarterly Performance and Key Drivers
Over the trailing quarter, NTRB's dominant theme was a sharp, liquidity-driven rally in a low-float micro-cap stock. Shares climbed from roughly $3.05 in late July to a peak near $9 by late September, more than doubling in about two months. Contributing factors included renewed investor attention on the AVERSA abuse-deterrent platform, the company's fifth-anniversary Nasdaq listing communication, ongoing intellectual-property and patent activity, and the approach of the September 30 warrant expiration, which focused attention on the stock's near-term capital structure.
On the fundamental side, Nutriband reported fiscal second-quarter results in early September showing revenue of about $0.44 million and a narrower net loss versus the prior-year period. Analyst coverage remained limited, with Noble Financial reiterating a Buy rating and a $15 price target in August. The pullback from late September largely unwound the speculative portion of the quarter's gains, leaving the stock sharply higher over the full three-month span despite the recent correction. One thing that stands out is how quickly sentiment can shift in this space.
Looking Ahead: Key Catalysts to Monitor
Looking ahead, the most important catalysts for Nutriband center on clinical and regulatory execution for AVERSA Fentanyl. Key milestones include manufacturing clinical supplies for the Human Abuse Liability study, filing an Investigational New Drug (IND) application with the FDA, and initiating clinical studies as the company works toward an eventual NDA filing. Progress on extending patent protection and additional intellectual-property filings also matter for the investment thesis.
Investors should also monitor quarterly earnings and cash position, given the company's limited revenue base and ongoing net losses, as well as analyst commentary and any future financing activity. As a small-cap stock with a beta above 1.9 and relatively thin trading volume, NTRB is likely to remain sensitive to shifts in risk appetite and broader biotech sentiment. These factors, rather than any single event, will shape how the stock trades in the quarters ahead. I’m watching this closely as the clinical timeline unfolds.
Using AI Tools in My Research Process
In my own work, I occasionally turn to Tickeron’s AI Trading Bots to see how automated strategies are positioned around volatile names like this one. The platform runs hundreds of strategies across thousands of tickers, and the trending section surfaces only the top performers. It gives a quick, data-driven view that complements fundamental analysis without replacing it. For investors looking at short-term swings or longer holds, reviewing these bots can add useful context on current market positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NTRB in +3.12% Uptrend, growing for three consecutive days on September 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NTRB advanced for three days, in 197 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRB moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRB as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRB turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NTRB moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTRB crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NTRB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NTRB entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. NTRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.581) is normal, around the industry mean (2.974). P/E Ratio (-12.143) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement